BARDA Backs Arcturus' Influenza Vaccine Program
BARDA Backs Arcturus' Influenza Vaccine Program
Barda支持Arcturus的流感疫苗计划
- Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).
- The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus' self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
- Also see: Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants.
- The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
- Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.
- Arcturus治疗控股公司纳斯达克(Sequoia Capital:ARCT)从生物医学高级研究与发展局(BARDA)获得了高达6,320万美元的奖金。
- 该奖项为期三年,用于支持临床前、生产和非临床安全性研究,以及对Arcturus的自我放大信使核糖核酸疫苗平台技术的开发和监管支持,以通过第一阶段研究快速应对大流行性流感。
- 另请参阅: 大角星的新冠肺炎助推器对奥密克戎变种表现出耐用性.
- 该公司表示,其自我放大的mRNA疫苗已在全球超过1万人接种,表现出良好的安全性、强大的免疫原性和对SARS-COV-2感染的保护作用。
- 价格行动:在周四的最后一次检查中,ARCT的股价下跌了2.68%,至13.66美元。